Hui-Hsien Lin

Assay Development Scientist @ Genesis Therapeutics | PhD in Chemistry | Cell Biology, Genome Editing, Data Analysis

Role: Scientist, Biology Cell Pharmacology at Genesis Molecular AI
Location: San Diego, CA, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Hui-Hsien Lin

What does it take to turn a biological hypothesis into a drug candidate? For me, it…

Experience

Scientist, Biology Cell Pharmacology
Genesis Molecular AI
Apr 2024 — Present · San Diego, CA, US

Education

National University of Kaohsiung
Bachelor of Science (B.S.)
2006 — 2010
University of Massachusetts, Amherst
Doctor of Philosophy (Ph.D.)
2013 — 2019
National University of Kaohsiung
Master of Science - MS
2010 — 2013

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@genesistherapeutics.ai
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Genesis Molecular AI

Biotechnology Research · 168 employees · Burlingame, California, United States

Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.

genesistherapeutics.ai

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Hui-Hsien Lin

Experience

Scientist, Biology Cell Pharmacology

Education

National University of Kaohsiung

University of Massachusetts, Amherst

National University of Kaohsiung

Find verified contacts for anyone on LinkedIn